Imcheck Therapeutics
Designing and developing a new generation of immunotherapy antibodies.
Launch date
Employees
Market cap
-
Enterprise valuation
€384—576m (Dealroom.co estimates Jun 2022.)
Company register number 812428142
Marseille Provence-Alpes-Côte d'Azur (HQ)
Financials
Estimates*
| EUR | 2016 | 2017 |
|---|---|---|
| EBITDA | - | (3.4m) |
| Profit | (1.2m) | (2.9m) |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | €20.0m | Series A | |
* | €1.0m | Early VC | |
$2.2m | Grant | ||
* | €48.0m | Series B | |
€6.0m Valuation: €240m | Series B | ||
* | €96.0m | Series C | |
* | €20.2m | Grant | |
| Total Funding | €193m | ||
Related Content
Recent News about Imcheck Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.